Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story
Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer
London, 2 May 2023 – Resolution Therapeutics announces the appointment of Dr. Clifford A. Brass, as Chief Medical Officer.
Resolution Expands its CMC Capabilities with Key Hires
London, 30 March 2023 - Resolution Therapeutics announces the appointment of key senior CMC hires in regulatory, quality, process development, analytical development and project management.
Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors
London, 9 November 2022 - Resolution announced today the appointment of Lisa Bright as Chairman of its Board of Directors
Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for iPSC-derived macrophage cell therapies
London, UK and Toronto, Canada, 7 November, 2022 – Resolution Therapeutics and CCRM announce the signing of a collaboration in iPSC-derived macrophage cell therapies.
Resolution Therapeutics Appoints Bill Symonds to its Board of Directors
London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.
Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer
London, 30 June, 2022 – Resolution Therapeutics announces the appointment of Dr. Amol Ketkar, as Chief Development Officer.
Resolution Therapeutics and panCELLa Inc announce a Research Evaluation and Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease
London and Toronto, 5 April 2022 - Resolution Therapeutics partners with panCELLa to develop iPSC-derived macrophage cell therapy for inflammatory organ disease.
Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd
London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease.
Resolution Therapeutics Strengthens its Team with Two New Appointments
London, 17 February 2022 – Resolution Therapeutics announces the strengthening of its senior management team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance.